CurifyLabs launches 3D printing solution for pharmacies – enables wider availability of patient-tailored medicine and better care for patients
CurifyLabs is a Finnish healthtech company developing 3D printing solutions for personalized medicine, modernizing the drug compounding process in pharmacies and hospitals.
The company is today launching the first-ever GMP-manufactured printable pharmaceutical inks for 3D printing of personalized medicines in pharmacies.
Using CurifyLabs' automated on-demand manufacturing concept, pharmacists have access to a library of printable inks for fast 3D printing in compliance with regulatory requirements.
HELSINKI, October 17th, 2023
CurifyLabs, a Finnish healthtech company, is the first to offer 3D printing of medicine as a scalable and practical service. Today, the company is launching GMP (good manufacturing practice) produced Pharma Inks for 3D printable medicines, providing a novel solution for producing patient-tailored and personalized medicines in pharmacies and hospitals. CurifyLabs' Pharma Kit, including automated 3D printing technology combined and printable pharmaceutical inks, enables wider adoption of personalized medicine, resulting in better future care for patients with different needs.
The demand for personalized medicine is increasing in healthcare. Genetic differences, age, gender, allergies, and disabilities can all affect how individuals react to medication. Mass production of medicine and standardized dosages can lead to ineffective treatment, side effects, and significant health risks for certain patients. Personalized treatment and medication are crucial, especially for patients in vulnerable situations like cancer patients and children. According to a report by the European Commission, currently, over 50% of medicines are not registered for use in children. Moreover, there is increasing evidence that pharmacogenetic testing in optimization of drug dosing reduces adverse reactions in patients.*
"There is a significant need for scalable and practical methods to produce customized drugs that precisely match a patient's needs. We are thrilled to introduce the world's first Pharma Ink for 3D printing of drugs and offer a solution for producing personalized medicines in pharmacies and hospitals efficiently and safely. This enables wider drug availability and better care for people with various medical conditions, particularly those in vulnerable situations where personalized treatment is the only option," says Charlotta Topelius, CEO and co-founder of CurifyLabs.
Currently, compounding – the preparation of personalized drug treatments – is done manually in pharmacies. Pharmacists measure and mix different ingredients to create medications tailored to specific patient requirements. While this practice ensures customization, it often comes at the cost of time and potential human errors, compromising efficiency and patient safety.
To address the operational, financial, regulatory, and clinical challenges hindering the wider adoption of personalized medicines, CurifyLabs has developed an automated on-demand manufacturing concept, the CurifyLabs Pharma Kit, allowing the production of personalized medicines onsite in pharmacies. CurifyLabs’ team of pharmacists has developed a variety of printable pharmaceutical inks, for a wide range of APIs that are commonly compounded in pharmacies today. With CurifyLabs Pharma Printer and Pharma Inks, pharmacists have access to a library of printable inks for fast 3D printing in compliance with regulatory requirements for the field.
“Pharmacy-tailored drug manufacturing is very laborious and involves manual work steps. We have been waiting for this type of technology”, says Catharina Kern, Pharmacist, at Münster University Hospital.
Niklas Sandler, CTO and Founder comments:“Pharmaceutical 3D printing automates the time-consuming manual compounding process, enabling pharmacists to efficiently produce custom medications while maintaining high manufacturing standards. The quality of all drugs produced are verified with in-process quality control tools with our solution. Our technology can save up to 70% of the time compared to manual methods.
“We’re happy to collaborate with CurifyLabs on this world premiere of printable pharmaceutical inks”, says Kathrin Bartscher, Chief Scientific Officer at NextPharma.
Making high-quality automated compounding accessible to all pharmacies and patients unlocks a unique opportunity in a rapidly growing market. According toGlobal Market Insights, the global compounding market was valued at $11 billion in 2022, and it is projected to reach $18.2 billion by 2030, driven by the increasing demand for personalized medication.
“With our 3D printing solutions, we aim to reshape the landscape of pharmacy-tailored medicines in hospital and compounding pharmacies. Our goal is to build foundations for a healthcare system that delivers not only customized medications but also greater convenience, enhanced patient safety, and time savings for pharmacists”, Topelius concludes.
CurifyLabs is a Finnish healthtech company developing 3D printing solutions for manufacturing personalized medicines in pharmacies and hospitals. CurifyLabs' automated on-demand manufacturing concept, “the Pharma Kit” and printable pharmaceutical inks, enable personalized mass customization of medicines, allowing patient safety and efficacy at a significantly lower cost. CurifyLabs was founded in 2021 by Charlotta Topelius and Niklas Sandler Topelius.
(1) Source:Swen JJ, van der Wouden CH, Manson LEN et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.Lancet. 2023; 401: 347-356